glp-1 oral Novel Pill Tops Semaglutide for Diabetes Novo Nordisk's oral GLP-1 drug
Description
Nausea is the most common complaint , affecting 20 to 40 percent of patients during initial dosing
More research is needed to understand the potential long-term effects of these medications on hair health and determine if specific risk factors predispose individuals to hair loss while undergoing treatment

"A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease (TRIUMPH-3) - Lilly Clinical Trials"
Its also slightly less potent for A1C reduction (average blood glucose over the past two to three months) in people with type 2 diabetes

Decreased self-administration of opioids such as heroin, fentanyl, and oxycodone in rodent models

What the Phase 3 Trial Found In the Phase 3 ATTAIN-1 trial, more than 3,000 adults with obesity or overweight received daily doses of orforglipron alongside lifestyle changes
